Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Robenidine SCHEMBL571509 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4 | |
| Robenidine SCHEMBL3851893 | 0.98 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4 | |
| Robenidine SCHEMBL11769699 | 0.98 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL19449644 | 0.91 | LMNA (0.58) | SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL11233334 | 0.91 | MEN1 (0.57) | SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL23874282 | 0.91 | MAPT (0.47) | SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL11233329 | 0.91 | MEN1 (0.57) | SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL16224325 | 0.91 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL11768892 | 0.90 | MEN1 (0.56) | SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL11768897 | 0.90 | MEN1 (0.56) | SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4310541-A | WITH A BIS(BENZYLIDENEAMINO)GUANIDINE | MERCK & CO., INC. (US) | 1982-01-12 | — | — | US | claimed |
| US-4041160-A | N-METHYL-2-PYRROLIDONE, ANTICOCCIDIAL AGENTS | ABIC LTD. (IL) | 1977-08-09 | — | — | US | claimed |
| US-3980705-A | Purification of robenidine hydrochloride | AMERICAN CYANAMID COMPANY (US) | 1976-09-14 | — | — | US | claimed |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | UNIVERSITAT AUTÒNOMA DE BARCELONA (ES) | 2023-05-11 | — | — | US | disclosed |
| US-11566012-B2 | Methods for treating protozoan infections | NEOCULI PTY LTD (AU) | 2023-01-31 | — | — | US | disclosed |
| EP-3960729-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | Neoculi Pty Ltd (AU) | 2022-03-02 | — | — | EP | disclosed |
| EP-2991968-B1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | NEOCULI PTY LTD (AU) | 2021-11-10 | — | — | EP | disclosed |
| US-20210009552-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2021-01-14 | — | — | US | disclosed |
| US-10829468-B2 | Methods for treating protozoan infections | NEOCULI PTY LTD. (AU) | 2020-11-10 | — | — | US | disclosed |
| US-20200290990-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2020-09-17 | — | — | US | disclosed |
| US-10752606-B2 | Methods for treating protozoan infections | NEOCULI PTY LTD. (AU) | 2020-08-25 | — | — | US | disclosed |
| US-20020123649-A1 | Process for the preparation of robenidine and salts thereof | LONZA AG (CH) | 2002-09-05 | — | — | US | disclosed |
| US-4310541-A | WITH A BIS(BENZYLIDENEAMINO)GUANIDINE | MERCK & CO., INC. (US) | 1982-01-12 | — | — | US | disclosed |
| US-4041160-A | N-METHYL-2-PYRROLIDONE, ANTICOCCIDIAL AGENTS | ABIC LTD. (IL) | 1977-08-09 | — | — | US | disclosed |
| US-3992446-A | ANTIPROTOZOAL ACTIVITY, PARTICULARLY AGAINST COCCIDIOSIS AND MALARIA | AMERICAN CYANAMID COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
| US-3980705-A | Purification of robenidine hydrochloride | AMERICAN CYANAMID COMPANY (US) | 1976-09-14 | — | — | US | disclosed |
| US-3954996-A | BACTERICIDES | ABIC LTD. (IL) | 1976-05-04 | — | — | US | disclosed |
| US-3954996-A | BACTERICIDES | ABIC LTD. (IL) | 1976-05-04 | — | — | US | disclosed |
| US-3950539-A | Substituted diaminoguanidines | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-04-13 | — | — | US | disclosed |
| US-3941825-A | ANTIPROTOZOA INTERMEDIATES | AMERICAN CYANAMID COMPANY (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566012-B2 | Methods for treating protozoan infections | DPM1, ABCB11, PIGS | SMN1; SMN2 3002/4885NPC1 282/4885RAB9A 3198/4885 |
| US-20200290990-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | SMN1; SMN2 3002/4885NPC1 282/4885RAB9A 3198/4885 |
| US-20210009552-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | SMN1; SMN2 3002/4885NPC1 282/4885RAB9A 3198/4885 |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | SNCA, PARK7, PRNP | SMN1; SMN2 6/4885NPC1 801/4885RAB9A 364/4885 |
| US-20020123649-A1 | Process for the preparation of robenidine and salts thereof | ADH1C, ADH1A, DRD4 | SMN1; SMN2 4689/4885NPC1 1482/4885RAB9A 511/4885 |
| US-10829468-B2 | Methods for treating protozoan infections | DPM1, ABCB11, PIGS | SMN1; SMN2 3002/4885NPC1 282/4885RAB9A 3198/4885 |
| US-10752606-B2 | Methods for treating protozoan infections | DPM1, ABCB11, PIGS | SMN1; SMN2 3002/4885NPC1 282/4885RAB9A 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.